Enhanced HBcAg immunoassay enables detection of clinically relevant low-level HBV viremia for treatment eligibility

The HBcAg v2 assay enables detection of low viral titers consistent with treatment guidelines and correlates directly with HBV DNA levels. Its ability to specifically detect low-abundance HBcAg enhances disease staging and may support therapeutic management, particularly in resource limiting settings.